Clinicopathological Factors Affecting Survival and Recurrence after Initial Hepatectomy in Non-B Non-C Hepatocellular Carcinoma Patients with Comparison to Hepatitis B or C Virus

Table 1

Lifestyle-related and preoperative clinical factors.

	B (𝑛=32)	C (𝑛=93)	NBNC (𝑛=76)	𝑃 value
Age (years)	61.1±13.6	67.2±6.6	71.0±9.2	<0.001
Gender (male/female)	23/9	70/23	67/9	0.058
Obesity	3 (9.4%)	17 (18.3%)	15 (19.7%)	0.412
Hypertension	6 (18.8%)	26 (28.0%)	36 (47.4%)	0.004
DM	5 (12.0%)	20 (21.5%)	27 (35.5%)	0.041
Cigarette smoking	19 (59.4%)	55 (59.1%)	47 (61.8%)	0.933
Ethanol ≧ 20 g	5 (15.6%)	38 (40.9%)	46 (60.5%)	<0.001
Albumin (g/dL)	3.6 (2.3–4.5)	3.7 (2.8–4.5)	3.8 (2.5–5.0)	0.104
Total bilirubin (mg/dL)	0.5 (0.2–1.2)	0.5 (0.2–1.4)	0.5 (0.2–1.3)	0.873
Platelet count (×10^4/mm^3)	14.0 (4.3–48.9)	16.1 (4.4–51.0)	19.2 (6.7–51.6)	0.020
NLR	2.21 (0.79–4.90)	1.92 (0.52–14.16)	2.16 (0.67–12.80)	0.271
PT (%)	82.9 (64.3–105.0)	90.0 (63.4–122.7)	95.4 (54.8–131.4)	0.002
ICG R15 (%)	12.7 (4.4–19.7)	14.0 (2.8–42.3)	10.9 (1.6–36.7)	0.027
Child-Pugh B/C	2 (6.3%)	5 (5.4%)	6 (7.9%)	0.802
AFP (ng/mL)	110.0 (1–605100)	14.0 (2–11675)	6.0 (1–48157)	<0.001
DCP (mAU/mL)	267.0 (10–174400)	148.0 (10–23950)	87.0 (11–85330)	0.653
Multiple tumors	10 (31.3%)	25 (26.9%)	22 (28.9%)	0.885
Tumor size (cm)	5.2 (1.0–20.0)	3.0 (0.7–11.0)	4.5 (1.0–17.0)	0.001
≧10 cm	7 (21.9%)	2 (2.2%)	14 (18.4%)	0.001
BCLC stage B/C	8 (25.0%)	16 (17.2%)	18 (23.7%)	0.484
Beyond Milan criteria	15 (46.9%)	26 (28.0%)	38 (50.0%)	0.009
Preoperative TACE	17 (53.1%)	60 (64.5%)	42 (55.3%)	0.356

DM: diabetes mellitus; NLR: neutrophil-to-lymphocyte ratio; PT: prothrombin time; ICG R15: indocyanine green retention rate at 15 minutes; AFP: serum 𝛼-fetoprotein; DCP: des-r-carboxyprothrombin; BCLC: Barcelona Clinic Liver Cancer; TACE: transcatheter arterial chemoembolization.